Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities: 2022-2024

Historic Total Non-Current Liabilities for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $593,000.

  • Corvus Pharmaceuticals' Total Non-Current Liabilities fell 48.64% to $321,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $321,000, marking a year-over-year decrease of 48.64%. This contributed to the annual value of $593,000 for FY2024, which is 8.49% down from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $593,000 for FY2024, which was down 8.49% from $648,000 recorded in FY2023.
  • Corvus Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $985,000 for FY2022, and its period low was $593,000 during FY2024.
  • Over the past 3 years, Corvus Pharmaceuticals' median Total Non-Current Liabilities value was $648,000 (recorded in 2023), while the average stood at $742,000.
  • Data for Corvus Pharmaceuticals' Total Non-Current Liabilities shows a maximum YoY crashed of 34.21% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Corvus Pharmaceuticals' Total Non-Current Liabilities stood at $985,000 in 2022, then plummeted by 34.21% to $648,000 in 2023, then dropped by 8.49% to $593,000 in 2024.